**

Lyon, France – October 26, 2023 – The global logistics landscape is set to shift significantly with Worldwide Flight Services (WFS) announcing ambitious plans to open a cutting-edge, pharma-ready cargo terminal at Lyon Saint-Exupéry Airport (LYS) in 2026. This major investment underscores the growing importance of Lyon as a central hub for pharmaceutical transportation within Europe and highlights the increasing demand for specialized, temperature-controlled air freight solutions. This new facility is poised to revolutionize pharmaceutical logistics, significantly impacting the cold chain logistics, pharma air freight, and temperature-sensitive cargo sectors.

Lyon's Strategic Location: A Gateway for Pharmaceutical Exports and Imports

Lyon’s strategic geographical position at the heart of Europe makes it an ideal location for a large-scale pharmaceutical cargo terminal. Its excellent connectivity via road, rail, and air networks provides seamless access to key markets across the continent and beyond. The region also boasts a thriving pharmaceutical industry, with numerous manufacturers, research facilities, and distribution centers already operating within the area. The new WFS terminal will further solidify Lyon’s position as a crucial European air freight hub and attract further investment in the life sciences sector. This development cements Lyon's place as a key player in the global pharmaceutical supply chain.

WFS's Pharma-Ready Terminal: A Technological Leap Forward

The planned WFS facility will be a state-of-the-art operation, designed specifically to handle the unique requirements of pharmaceutical products. This isn't just another cargo terminal; it will represent a substantial upgrade to the existing infrastructure supporting pharmaceutical logistics. Key features include:

Advanced Temperature Control and Monitoring

• Real-time temperature monitoring: Sophisticated sensor technology will provide continuous monitoring and tracking of temperature throughout the entire handling process, ensuring the integrity of temperature-sensitive medications.
• Multiple temperature zones: The terminal will accommodate various temperature requirements, including ambient, chilled, and frozen storage, making it suitable for a wide range of pharmaceutical products.
• Redundant systems: Backup power and refrigeration systems will guarantee uninterrupted temperature control, even in the event of power outages or equipment malfunctions.

Enhanced Security and Compliance

• 24/7 security surveillance: Robust security measures will be implemented throughout the facility to prevent unauthorized access and ensure the safety and security of pharmaceutical shipments.
• GDP (Good Distribution Practice) compliance: The terminal will be designed and operated in strict compliance with GDP guidelines to meet the stringent regulatory requirements of the pharmaceutical industry. This ensures compliance with EU GMP guidelines and other international standards.
• Advanced traceability systems: Real-time tracking and tracing capabilities will provide complete visibility of shipments throughout the supply chain, enhancing efficiency and accountability.

Streamlined Handling Processes

• Automated material handling systems: The terminal will leverage automated systems to improve efficiency and reduce handling times, minimizing the risk of damage or temperature excursions.
• Dedicated pharmaceutical handling teams: Highly trained personnel with specialized expertise in pharmaceutical logistics will manage all aspects of handling, storage, and transportation.
• Efficient customs clearance processes: Streamlined procedures will ensure rapid and efficient customs clearance, reducing delays and minimizing the risk of spoilage.

The Impact on the Pharmaceutical Industry

The opening of this new pharma-ready terminal in Lyon is expected to have a far-reaching impact on the pharmaceutical industry. Here are some key benefits:

• Improved supply chain efficiency: The advanced technology and streamlined processes will significantly improve the efficiency and reliability of pharmaceutical transportation within Europe.
• Reduced risk of product damage: The advanced temperature control and handling systems will reduce the risk of product spoilage or degradation, ensuring the quality and efficacy of medications.
• Enhanced patient safety: By maintaining the integrity of temperature-sensitive drugs, the terminal will help ensure patient safety and contribute to better health outcomes.
• Economic growth in Lyon and the Auvergne-Rhône-Alpes region: The new facility will create numerous jobs and attract further investment in the region, stimulating economic growth.
• Increased competitiveness for European pharmaceutical companies: Access to a state-of-the-art pharmaceutical cargo terminal will make European companies more competitive in the global pharmaceutical market.

Conclusion: A New Era for Pharmaceutical Logistics in Europe

WFS’s investment in Lyon represents a significant step forward for pharmaceutical logistics in Europe. The new pharma-ready terminal will not only improve the efficiency and reliability of pharmaceutical transportation but also enhance safety and security. Lyon's strategic location, combined with WFS’s commitment to cutting-edge technology and expertise, positions the city as a leading hub for the pharmaceutical industry. The 2026 opening of this facility marks a pivotal moment, setting a new benchmark for pharma logistics and potentially influencing similar developments across Europe and globally. This is a major boost to the air cargo industry and underscores the growing importance of specialized infrastructure to support the complex needs of the life sciences supply chain. The development significantly enhances Lyon’s status within the global logistics network.